About Fennec Pharmaceuticals Inc. - Common Stock (FENC)
Fennec Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative treatments for patients with cancer. The company primarily specializes in therapies that address the unmet medical needs associated with cancer-related side effects, particularly those related to chemotherapy-induced toxicity. By leveraging its proprietary drug formulations, Fennec aims to improve the safety and effectiveness of cancer treatments, enhancing the quality of life for patients undergoing chemotherapy. Their commitment to research and development drives efforts to expand their product pipeline and bring new, transformative therapies to market. Read More
Adherex Technologies (NASDAQ:FENC) executives said Fennec Pharmaceuticals entered 2026 with stronger commercial momentum for PEDMARK, reporting higher first-quarter sales, positive operating cash flow and early signs that recent sales force investments are increasing demand.
On the company’s first-
RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2026 financial results before the opening of the U.S. financial markets on Thursday, May 14, 2026. Management will host a conference call and webcast that day to discuss the Company’s financial and business results.
Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQ:TSLA) and Palantir Technologies, Inc.
FENC stock results show that Fennec Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
FENC stock results show that Fennec Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
